These findings generally suggest that patients in this clinical context tend to derive the greatest benefit from therapies with documented efficacy within the same cancer entities in early trials or case reports, as well as from established treatment modalities in other cancer types such as NTRK inhibitors or BRAF/MEK inhibitors33,34. This evidence concerns the gene MAP2K7 and cancer.